Speedier drug approvals hit slowdown as FDA faces scrutiny
The Food and Drug Administration is slowing its use of a pathway that expedites the approval of promising drugs
Stay updated with breaking news from Sam Kay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration is slowing its use of a pathway that expedites the approval of promising drugs
Expedited drug approvals slowed this year as the Food and Drug Administration's contentious accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency's own leaders.
The FDA’s drug center granted 10 accelerated approvals — fewer than the tally in each of the last five years.
Increasingly, the FDA is asking drugmakers to remove unproven uses from older drugs that haven't delivered on early results. And drugmakers seeking accelerated approvals are facing tougher hurdles.
With less than a month remaining in the year, the FDA's drug center has granted 10 accelerated approvals.